Crescent Grove Advisors LLC cut its position in Pfizer (NYSE:PFE) by 5.4% during the 4th quarter, Holdings Channel reports. The firm owned 29,823 shares of the biopharmaceutical company’s stock after selling 1,691 shares during the quarter. Crescent Grove Advisors LLC’s holdings in Pfizer were worth $1,080,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently modified their holdings of PFE. Vanguard Group Inc. raised its position in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after buying an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after buying an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after buying an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Pfizer by 3.6% during the 4th quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock worth $1,317,407,000 after buying an additional 1,251,550 shares in the last quarter. Hedge funds and other institutional investors own 71.33% of the company’s stock.
In other news, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the transaction, the insider now directly owns 36,959 shares in the company, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is currently owned by insiders.
A number of analysts have commented on the stock. Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “hold” rating in a research report on Friday, April 13th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, April 12th. Citigroup reaffirmed a “sell” rating on shares of Pfizer in a research note on Thursday, April 12th. Berenberg Bank reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Pfizer in a research note on Wednesday, April 11th. Finally, Barclays cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $41.00 to $38.00 in a research note on Thursday, April 5th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $39.20.
Pfizer stock opened at $37.06 on Wednesday. The company has a market capitalization of $218,053.44, a PE ratio of 13.98, a PEG ratio of 1.83 and a beta of 0.90. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. Pfizer has a fifty-two week low of $31.67 and a fifty-two week high of $39.43.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. equities research analysts predict that Pfizer will post 2.96 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Crescent Grove Advisors LLC Sells 1,691 Shares of Pfizer (PFE)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/25/crescent-grove-advisors-llc-sells-1691-shares-of-pfizer-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.